Bio-Rad price target raised to $340 from $265 at Wells Fargo

Wells Fargo raised the firm’s price target on Bio-Rad (BIO) to $340 from $265 and keeps an Equal Weight rating on the shares. The firm says shares of Bio-Rad should be flat on the in-line quarter and stable full year guide. Not surprisingly, Bio-Rad is cautious on 2026 growth prospects, but still expects to deliver margin expansion even on muted revenue growth, Wells adds.